Third Rock funds gene therapy startup Voyager with $45m
This article was originally published in Scrip
Executive Summary
The early-stage biotechnology funder Third Rock Ventures reinforced its belief that gene therapy is an idea whose time has come by investing $45m in the startup Voyager Therapeutics.
You may also be interested in...
Voyager Cheers End Of Sanofi Partnership In Parkinson's; Investors Less Confident
The gene therapy developer described Sanofi's decision to give up ex-US rights to VY-AADC01 as good news, but its stock price fell anyway. Voyager maintains that it wasn't necessarily counting on its partner to opt in, so it has enough funding without Sanofi to conduct a Phase II/III study.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.